

Name: Jan Alexander Michael van Laar
Address: Internal Medicine, Section of Clinical Immunology
Erasmus University Medical Center Rotterdam
Postbus 2040
3000 CA Rotterdam, The Netherlands
Tel.: +31617334973
E-mail: j.vanlaar@erasmusmc.nl
BIG: 49044020301
ABG: 03100236
Orchid id: <https://orcid.org/0000-0002-8885-4929>
Title: Ph.D. (08-03-1996), M.D., Associate Professor (31-10-2019)

Education:

Study: Medicine, Free University, Amsterdam: 01-09-1985 - 04-11-1994.
Specialization: Internist, Erasmus University Medical Center Rotterdam, 31-12-2001.
Superspecialization: Internist-oncologist, Erasmus University Medical Center Rotterdam,
location Daniel den Hoed Clinic: 31-12-2003.
Internist-immunologist, Erasmus University Medical Center Rotterdam,
31-12-2006

Field of study:

Immunological, histological and clinical aspects of:

- Behçet's Disease
- Histiocytic Disorders
- IgG4 related disease
- Sarcoidosis and uveitis

Current Work:

- 2005- current date: staff member section Immunology, department of internal medicine, EMCR.

Work:

- Student assistant, Oncology, section Biochemical Pharmacology, AZVU, Amsterdam: February - June 1990.
- Research assistant, Oncology, section biochemical Pharmacology, AZVU, Amsterdam: September 1990 - March 1991.
- Visiting clinical scientist, Oncology, Experimental Therapeutics, Grace Cancer drug Centre, Roswell park Cancer Institute, April 1991 - March 1992.
- Research worker, Oncology, section biochemical Pharmacology, AZVU, Amsterdam: December 1994 till March 1995.
- AGNIO (residency) internal medicine OLVG, Amsterdam: 01-07-1995 - 01-04-1996.
- AGNIO (residency) internal medicine EMCR: 01-07-1996 - 31-12-1996.
- AGIO (residency) internal medicine EMCR: 1997 - 2001.
- 2002-2003, internist specializing to oncologist, EMCR location Daniel den Hoed Clinic
- 2004: chef clinique/ internist-oncologist, St. Elisabeth hospitaal, Curaçao, Netherlands Antilles

Thesis:

Modulations of 5-fluorouracil and 5-fluoro-2'-deoxyuridine. Free University, Amsterdam. ISBN 90-9009246-3, Febodruk, Enschede, 1996. Thesis presentation 08-03-1996, Amsterdam.

Co-promotor PhD defenses:

- J.H. Kappen: Translational Aspects of Behçet's Disease, May 19th 2015
- L.S.J. Kamphuis : The Many Faces of Sarcoidosis, May 25th 2016
- W.M.C. Timmermans: Immunopathogenesis of granulomas in chronic inflammatory diseases, October 20th 2018
- F. Hakan-Groen: Diagnosing Uveitis: Value and Limitations of Current Diagnostic Tests, April 10th 2019
- A.F. Karim: IgG4-Related Disease: Insights in the pathogenesis, clinical presentations, diagnostics and treatment, October 16th 2019
- T. van der Houwen: Immunological and Clinical Aspects of Behçet's Disease. May 18th 2022.
- L.E.M. Eurelings: The Immunology of Sarcoidosis, May 10th 2022
- T.E. Zondag: Klinische, immunologische en genetische aspecten van histiocytair ziekten. 20-09-2023.
- S. Detiger: Due 2024: orbital IgG4RD

Memberships:

- NIV, ISBD, HIS, NVVIAKI
- Council an Board ISBD, treasurer ISBD
- IHS supervised HLH-adult study group
- ECHO, European Consortium for Histiocytosis. Member at large adult ECHO focus group
- Steering committee ERN ReCONNET-IgG4RD working group
- Board HOVON Histiocytic and Lymphocytic Diseases Working group.

Publications 2023-2024

1. Hines MR, von Bahr Greenwood T, Beutel G, Beutel K, Hays JA, Horne A, Janka G, Jordan MB, van Laar JAM, Lachmann G, Lehmborg K, Machowicz R, Miettunen P, La Rosée P, Shakoory B, Zinter MS, Henter JI. Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. *Crit Care Med*, 2022 May 1;50(5):860-872. doi: 10.1097/CCM.0000000000005361. Epub 2021 Oct 5.
2. van der Wouden K.E., Teunis C.J., van Laar J.A.M. Karim, A.F. Sarcoïdose: de huidige stand van zaken. *NED TIJDSCHR ALLERGIE, ASTMA, KLIN IMMUNOL* 2021;21(4):142–8
3. Kemps PG, Picarsic J, Durham BH, Hélias-Rodzewicz Z, Hiemcke-Jiwa LS, van den Bos C, van de Wetering MD, van Noesel CJM, van Laar JA, Verdijk RM, Flucke UE, Hogendoorn PCW, Woei-A-Jin FJSH, Scirot R, Beilken A, Feuerhake F, Ebinger M, Möhle R, Fend F, Bornemann A, Wiegering V, Ernestus K, Méry T, Gryniowicz-Kwiatkowska O, Dembowska-Baginska B, Evseev DA, Potapenko V, Baykov VV, Gaspari S, Rossi S, Gessi M, Tamburrini G, Héritier S, Donadieu J, Bonneau-Lagacherie J, Lamaison C, Farnault L, Freitag S, Jullie ML, Haroche J, Collin M, Allotey J, Madni M, Turner K, Picton S, Barbaro PM, Poulin A, Tam IS, El Demellawy D, Empringham B, Whitlock JA, Raghunathan A, Swanson AA, Suchi M, Brandt JM, Yaseen NR, Weinstein JL, Eldem I, Sisk BA, Sridhar V, Atkinson MM, Massoth LR, Hornick JL, Alexandrescu S, Yeo KK, Petrova-Drus K, Peeke SZ, Munoz-Arcos L, Leino DG, Grier DD, Lorsbach R, Roy S, Kumar AR, Garg S, Tiwari N, Schafernak KT, Henry MM, van Halteren AGS, Abula O, Diamond EL, Emile JF. ALK+ histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. *Blood*. 2022 Jan 13;139(2):256-280.
4. van Laar JA. Can SARS-CoV-2 vaccinations induce auto inflammatory diseases? *Rheumatology (Oxford)*. 2022 ;61(S12):SI110-SI111. doi:10.1093/rheumatology/keac008. Online ahead of print.
5. van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Behçet's disease and treatment modalities. *Semin Arthritis Rheum*. 2022 Jan 10;52:151956. doi: 10.1016/j.semarthrit.2022.151956. Online ahead of print.
6. Schrijver B, La Distia Nora R, Nagtzaam NMA, van Laar JAM, van Hagen PM, Dik WA. Serum CCL17 distinguishes sarcoid uveitis from TB-uveitis and QFT-negative uveitis. *Acta Ophthalmol*. 2022 Jan 26. doi: 10.1111/aos.15093.
7. Iaccarino L, Talarico R, Bozzalla-Cassione E, Burmester GR, Culver EL, Doria A, Ebbo M, van Hagen PM, Hachulla E, van Laar JAM, Lanzillotta M, Martinez-Valle F, Montecucco C, Monti S, Nalli C, Schleinitz N, Tincani A, Della Torre E, Alexander TBlood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners. *Clin Exp Rheumatol*. 2022 Mar 1. Online ahead of print.
8. Detiger SE, Paridaens D, Verdijk RM, van Laar JAM, Dammers R, Monserez DA, Nagtegaal AP. Vision loss due to IgG4-related disease of the skull base, complicated by a mucocele of the sphenoid sinus. *Int Forum Allergy Rhinol*. 2022 Mar 16.
9. Goyal G, Tazi A, Go RS, Rech KL, Picarsic J, Vassallo R, Young JR, Cox CW, van Laar JA, Hermiston ML, Cao XX, Makras P, Kaltsas G, Haroche J, Collin M, McClain KL, Diamond EL, Girschikofsky M. Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. *Blood*. 2022 Mar 10;blood.2021014343.
10. Eurelings LEM, Missotten TOAR, van Velthoven MEJ, van Daele PLA, van Laar JAM, van Hagen PM, Thiadens AAHJ, Rombach SM. Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of

- therapy. *Am J Ophthalmol.* 2022 Mar 18;S0002-9394(22)00108-8. doi: 10.1016/j.ajo.2022.03.017.
11. Detiger SE, Paridaens D, van Hagen M, Karim F, van Laar JAM, Verdijk RM. Tissue IgG2/IgG4 Ratio as an Additional Tool to Distinguish IgG4-Related Disease From Other Fibroinflammatory Disorders. *Appl Immunohistochem Mol Morphol.* 2022 Jun 3.
 12. Falck D, van Laar J.A.M., Wokke, B. Neurologische manifestatie van de ziekte van Behçet. *Tijdschr Neurol Neurochir* 2022;123(4):141–8
 13. den Otter AAS, van der Houwen TB, van Hagen PM, van Laar JAM Clinical course of COVID-19 infections in patients with Behçet's disease in the Netherlands. *Clin Exp Rheumatol.* 2022 Jul 1. doi: 0.55563/clinexprheumatol/xdx09v.
 14. Zondag TCE, Torralba-Raga L, Van Laar JAM, Hermans MAW, Bouman A, Hollink IHIM, Van Hagen PM, Briggs DA, Hume AN, Bryceson YT. Novel RAB27A Variant Associated with Late-Onset Hemophagocytic Lymphohistiocytosis Alters Effector Protein Binding. *J Clin Immunol.* 2022 Jul 23. doi: 10.1007/s10875-022-01315-4.
 15. Ghuijs W, Kemps PG, Capala ME, Verdijk RM, van Halteren AGS, van der Wal RJP, van Laar JAM. Aggressive unifocal bone Langerhans cell histiocytosis with soft tissue extension both responsive to radiotherapy: a case report. *Radiat Oncol.* 2022;17(1):137. doi: 10.1186/s13014-022-02108-0.
 16. Kemps PG, Zondag TC, Arnardóttir HB, Solleveld-Westerink N, Borst J, Steenwijk EC, van Egmond D, Swennenhuis JF, Stelloo E, Trambusti I, Verdijk RM, van Noesel CJ, Cleven AH, Scheijde-Vermeulen M, Koudijs MJ, Krsková L, Hawkins C, Egeler RM, Brok J, von Bahr Greenwood T, Svojgr K, Beishuizen A, van Laar JA, Poetschger U, Hutter C, Sieni E, Minkov M, Abła O, van Wezel T, van den Bos C, van Halteren AGS. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study. *Blood Adv.* 2023 Feb 28;7(4):664-679. doi: 10.1182/bloodadvances.2022007947.
 17. Israni M, Nicholson B, Mahlaoui N, Obici L, Rossi-Semerano L, Lachmann H, Hayward G, Avramović MZ, Guffroy A, Dalm V, Rimmer R, Solis L, Villar C, Gennery AR, Skeffington S, Nordin J, Warnatz K, Korganow AS, Antón J, Cattalini M, Amin T, Berg S, Soler-Palacin P, Burns SO, Campbell M; RITA-ERN Transition Working Group Consortium. Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey. *J Clin Immunol.* 2023 Oct 12. doi: 10.1007/s10875-022-01345-y. Online ahead of print.
 18. Detiger SE, Hötte GJ, Verdijk RM, de Keizer ROB, van Hagen PM, van Laar JAM, Paridaens D. Adult orbital xanthogranuloma: long-term follow-up of treated cases. *Eye (Lond).* 2023 Aug;37(12):2475-2481. doi: 10.1038/s41433-022-02357-z. Epub 2022 Dec 16.
 19. Zondag TCE, Lika A, van Laar JAM. The role of etoposide in the treatment of adult patients with hemophagocytic lymphohistiocytosis. *Exp Hematol Oncol.* **2023** Jan 9;12(1):2.
 20. van der Groef R, de Jong PHP, Hijnen DJ, van der Woude CJ, van Laar JAM, van der Kuy PHM, Brugma JD, Pasma A. Impact of the First SARS-CoV-2 Lockdown on Adherence to Biological Treatment in Patients with Immune-Mediated Inflammatory Diseases in the Netherlands. *Patient Prefer Adherence.* **2023** Jan 19;17:167-174. doi: 10.2147/PPA.S392290. eCollection 2023.
 21. van der Houwen TB, Humer B, Missotten TO, Thiadens AAHJ, van Hagen PM, van Laar JAM. Long-term data on efficacy and safety of adalimumab in Behçet's disease. *Clin Immunol.* **2023** Jan 27:109242. doi: 10.1016/j.clim.2023.109242.
 22. Fragoulis GE, Bertsias G, Bodaghi B, Gul A, van Laar J, Mumcu G, Saadoun D, Tugal-Tutkun I, Hatemi G, Sfikakis PP. Treat to target in Behçet's disease: Should we follow the paradigm of other systemic rheumatic diseases? *Clin Immunol.* **2023** Jan;246:109186. doi: 10.1016/j.clim.2022.109186. Epub 2022 Nov 21.
 23. Looijen AEM, van Linschoten RCA, Brugma JD, Hijnen DJ, de Jong PHP, van der Kuy PHM, van Laar JAM, van der Woude CJ, Pasma A. Digital Outcome Measurement to

- Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry JMIR Res Protoc. **2023** Mar 30;12:e43230.
24. van Laar JAM, ten Berge, J.C.E.M. Het oog als spiegel van het immuunsysteem; diagnostiek en behandeling van uveïtis. (Ned Tijdschr Allergie, Aastma, Klin Immunol. **2023**;23(2):52-6)
 25. van Bilsen K, Vergouwen DPC, van Velthoven MEJ, Missotten TOAR, Rombach SM, van Zelm MC, Berkowska MA, van Hagen PM, Kuijpers RWAM, van Laar JAM. Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring. Ocul Immunol Inflamm. **2023** Jul 12:1-6. doi: 10.1080/09273948.2023.2229900. Online ahead of print.
 26. Acosta-Medina AA, Kemps PG, Zondag TC, Abeykoon JP, Forma-Borst J, Steenwijk EC, Feijen EAM, Teepen JC, Bennani NN, Schram SM, Shah MV, Davidge-Pitts C, Koster MJ, Ryu J, Vassallo R, Tobin WO, Young JR, Dasari S, Rech KL, Ravindran A, Cleven AH, Verdijk RM, van Noesel CJM, Balgobind BV, Bouma GJ, Saeed P, Bramer JAM, de Groen RA, Vermaat JSP, van de Sande MAJ, Smit EF, Langerak AW, van Wezel T, Tonino SH, van den Bos C, van Laar JA, Go RS, Goyal G, van Halteren AGS. BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis. Blood. **2023** Aug 18: blood.2023021212. doi: 10.1182/blood.2023021212.
 27. Van Laar JAM. Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis. Haematologica. **2024** Feb 1;109(2):374-375. doi: 10.3324/haematol.2023.283915.
 28. De Kok LGC, Mathieu van der Jagt M, van Laar JAM, Endeman H. Intravenous immunoglobulin treatment in COVID-19: friend or foe to tackle hyperinflammation? A case report. De intensivist, mei 2023.
<https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwizgc2Sq9eBAxV31qIHHebkAdsQFnoECA0QAQ&url=https%3A%2F%2Fde-intensivist.nl%2Fjaargang-31-editie-2-mei-2023%2F&usq=AOvVaw329vfWX7tyl8UbKxOS0bys&opi=89978449>.
 29. Segers F, van Laar JA, Wijbenga JA, de Ruitter GC. Extensive, circumferential, epidural spinal cord compression by IgG4-related pachymeningitis. BMJ Case Rep. **2023** Dec 28;16(12):e251381. doi: 10.1136/bcr-2022-251381.
 30. Oei L, Li J, Karim AF, Verdijk RM, Oei EHG, van Laar JAM, Ten Cate D, Haitsma I, Monserez DA, Zillikens MC. A dens fracture case solved. Rheumatology (Oxford). **2024** Feb 8: keae026. doi: 10.1093/rheumatology/keae026.
 31. Oosterveer L., Saleh L., Jansen L., van Laar J.A.M., Verdurmen K.J.M. Hemofagocytair syndroom in de zwangerschap. Nederlands Tijdschrift voor Obstetrie & Gynaecologie vol. 137, januari **2024**; p 26-29.
 32. van der Houwen TB, Annink ME, Roelofs JJTH, Takkenberg RB, van Laar JAM, van der Weerd NC, Hak AE, Kwakernaak AJ. Porto-sinusoidal vascular disorder and nephrotic-range proteinuria due to venous vasculitis in Behçet's disease. Clin Immunol. **2024** Apr 10:110207. doi: 10.1016/j.clim.2024.110207. Online ahead of print.
 33. Detiger SE, Paridaens D, Kemps PG, van Halteren AGS, van Hagen PM, van Laar JAM, Verdijk RM. Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations. Clin Immunol. 2024 Jun 25;265:110299. doi: 10.1016/j.clim.2024.110299.

Rotterdam, 29-07-2024



JAM van Laar